ConductScience.org, home

Paper42012295

Construction and characterization of novel Mycobacterium tuberculosis-derived triple and quadruple knockout vaccines against tuberculosis.

Garnica O and 13 others. Infect Immun, 2026. Cited by 0 papers, by iCite.

Cite this record

ConductScience Library. Construction and characterization of novel Mycobacterium tuberculosis-derived triple and quadruple knockout vaccines against tuberculosis. Papers, record 42012295. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42012295

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Construction and characterization of novel Mycobacterium tuberculosis-derived triple and quadruple knockout vaccines against tuberculosis.
PubMed
Journal
Infect Immun
PubMed
Year
2026
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
0
iCite
Revised in PubMed
2026-09-22
PubMed

Authors14

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Garnica OOmar
2Veerapandian RRaja
3Das KKishore
4Mishra AAbhishekhttps://orcid.org/0000-0003-2077-0937
5Rawat VVarsha
6Carmona AAreanna
7Chauhan VVivek
8Kumar RRakesh
9Chacon JJessica
10Khan AArshad
11Ramos EIEnrique I
12Gadad SSShrikanth S
13Jagannath CChinnaswamyhttps://orcid.org/0000-0002-3014-2857
14Dhandayuthapani SSubramanianhttps://orcid.org/0009-0001-4390-3811

Source PubMed

Download CSV of authors

Topics11

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Mycobacterium tuberculosisMajor topic
Tuberculosis VaccinesMajor topic
TuberculosisMajor topic
Animals
Mice
Female
Gene Knockout Techniques
Vaccines, Attenuated
Bacterial Proteins
Disease Models, Animal
Gene Deletion

Source PubMed

Download CSV of topics

Grants11

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
1R15AI156647; 1RO1AI175837National Institute of Allergy and Infectious DiseasesR15AI156647PubMedNIH RePORTER
R01 AI184394NIAID NIH HHSUnited StatesR01AI184394PubMedNIH RePORTER
R16GM149497NIGMS NIH HHSUnited StatesR16GM149497PubMedNIH RePORTER
R01AI161015, R01AI184551, R01AI184394, R01AI187440National Institute of Allergy and Infectious DiseasesR01AI161015PubMedNIH RePORTER
R01 AI187440NIAID NIH HHSUnited StatesR01AI187440PubMedNIH RePORTER
R01 AI175837NIAID NIH HHSUnited StatesR01AI175837PubMedNIH RePORTER
R15 AI156647NIAID NIH HHSUnited StatesR15AI156647PubMedNIH RePORTER
R01 AI184551NIAID NIH HHSUnited StatesR01AI184551PubMedNIH RePORTER
R01 AI161015NIAID NIH HHSUnited StatesR01AI161015PubMedNIH RePORTER
RSG-22-170-01-RMCAmerican Cancer SocietyPubMedPubMed
R16 GM149497NIGMS NIH HHSUnited StatesR16GM149497PubMedNIH RePORTER

Download CSV of grants

References72

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
131064713Enhanced delivery of Mycobacterium tuberculosis antigens to antigen presenting cells using RVG peptide.Tuberculosis (Edinb)2019https://conductscience.org/library/papers/31064713PubMed
227079235Mycobacterium tuberculosis EIS gene inhibits macrophage autophagy through up-regulation of IL-10 by increasing the acetylation of histone H3.Biochem Biophys Res Commun2016https://conductscience.org/library/papers/27079235PubMed
328942172Antigen 85 complex as a powerful Mycobacterium tuberculosis immunogene: Biology, immune-pathogenicity, applications in diagnosis, and vaccine design.Microb Pathog2017https://conductscience.org/library/papers/28942172PubMed
417671656Enhanced priming of adaptive immunity by a proapoptotic mutant of Mycobacterium tuberculosis.J Clin Invest2007https://conductscience.org/library/papers/17671656PubMed
538022657Recent advance in the development of tuberculosis vaccines in clinical trials and virus-like particle-based vaccine candidates.Front Immunol2023https://conductscience.org/library/papers/38022657PubMed
637828070Key advances in vaccine development for tuberculosis-success and challenges.NPJ Vaccines2023https://conductscience.org/library/papers/37828070PubMed
737654500Advances in protein subunit vaccines against tuberculosis.Front Immunol2023https://conductscience.org/library/papers/37654500PubMed
824349004ESAT-6 (EsxA) and TB10.4 (EsxH) based vaccines for pre- and post-exposure tuberculosis vaccination.PLoS One2013https://conductscience.org/library/papers/24349004PubMed
912368434Specialized transduction: an efficient method for generating marked and unmarked targeted gene disruptions in Mycobacterium tuberculosis, M. bovis BCG and M. smegmatis.Microbiology (Reading)2002https://conductscience.org/library/papers/12368434PubMed
1022574140The fbpA/sapM double knock out strain of Mycobacterium tuberculosis is highly attenuated and immunogenic in macrophages.PLoS One2012https://conductscience.org/library/papers/22574140PubMed
1127222470Deletion of nuoG from the Vaccine Candidate Mycobacterium bovis BCG ΔureC::hly Improves Protection against Tuberculosis.mBio2016https://conductscience.org/library/papers/27222470PubMed
129148954Arrest of mycobacterial phagosome maturation is caused by a block in vesicle fusion between stages controlled by rab5 and rab7.J Biol Chem1997https://conductscience.org/library/papers/9148954PubMed
1324890836Novel vaccination strategies against tuberculosis.Cold Spring Harb Perspect Med2014https://conductscience.org/library/papers/24890836PubMed
1421471301Relief from Zmp1-mediated arrest of phagosome maturation is associated with facilitated presentation and enhanced immunogenicity of mycobacterial antigens.Clin Vaccine Immunol2011https://conductscience.org/library/papers/21471301PubMed
1525657094Deletion of zmp1 improves Mycobacterium bovis BCG-mediated protection in a guinea pig model of tuberculosis.Vaccine2015https://conductscience.org/library/papers/25657094PubMed
1625869896Increased protective efficacy of recombinant BCG strains expressing virulence-neutral proteins of the ESX-1 secretion system.Vaccine2015https://conductscience.org/library/papers/25869896PubMed
1736475477[Genetic Engineering in Mycobacteria].Mol Biol (Mosk)2022https://conductscience.org/library/papers/36475477PubMed
1815958066Immunogenicity and protective efficacy of the Mycobacterium tuberculosis fadD26 mutant.Clin Exp Immunol2005https://conductscience.org/library/papers/15958066PubMed
1918946503PhoP: a missing piece in the intricate puzzle of Mycobacterium tuberculosis virulence.PLoS One2008https://conductscience.org/library/papers/18946503PubMed
2028297677Recombinant BCG Expressing ESX-1 of Mycobacterium marinum Combines Low Virulence with Cytosolic Immune Signaling and Improved TB Protection.Cell Rep2017https://conductscience.org/library/papers/28297677PubMed

See all 72 referencesDownload CSV of references

Cited by1

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 0 citations.

PMIDTitleJournalYearIn Papers
42792714Role of Exosomes During Mycobacterium Tuberculosis Infection: A Double-Edged Sword.Biomedicines2026https://conductscience.org/library/papers/42792714

Source PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/42012295

GET https://conductscience.org/api/papers/v1/42012295/references?page=2